Advances in the treatment of CD30 positive lymphoma with brentuximab vedotin.
10.3760/cma.j.issn.0253-2727.2023.01.018
- Author:
Ming Ci CAI
1
;
Peng Peng XU
1
;
Wei Li ZHAO
1
Author Information
1. National Research Center for Translational Medicine, State Key Laboratory of Medical Genomics; Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai 200025, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Brentuximab Vedotin;
Ki-1 Antigen;
Antineoplastic Agents;
Immunoconjugates/therapeutic use*;
Lymphoma/drug therapy*
- From:
Chinese Journal of Hematology
2023;44(1):81-86
- CountryChina
- Language:Chinese
